With the advent of technologies that allow simultaneous genotyping of thousands of singlenucleotide polymorphisms (SNPs) across the genome, the genetic contributions to complex diseases can be explored at an unprecedented detail. This study is among the first to apply the genome-wide association study (GWAS) approach to Alzheimer disease (AD). We present our GWAS results from the German population for genes included in the 'Top Results' list on the AlzGene database website. In addition to the apolipoprotein E locus, we identified nominally significant association signals in six of the ten genes investigated, albeit predominantly for SNPs other than those already published as being disease associated. Further, all of the four AD genes previously identified through GWAS also showed nominally significant association signals in our data. The results of our comparative study reinforce the necessity for replication and validation, not only of GWAS but also of candidate gene case-control studies, in different populations. Furthermore, cross-platform comparison of genotyping results can also identify new association signals. Finally, our data confirm that GWAS, regardless of the platform, are valuable for the identification of genetic variants associated with AD.
Introduction
Alzheimer disease (AD; MIM 104300) is a progressive neurodegenerative disease that is characterised by amyloid plaques (brain deposits of a sticky protein called amyloid-b (Ab) peptide) and neurofibrillary tangles (abnormally twisted forms of the protein-t, in the long branches of neurons). AD has a multifactorial aetiology involving a complex interaction of both genetic and environmental factors. Nevertheless, four genes are unequivocally associated with AD. Mutations in three of these genes, encoding amyloid precursor protein (APP; MIM 104760), presenilin 1 (PSEN1; MIM 104311) and presenilin 2 (PSEN2; MIM 600799) invariably lead to the development of an autosomal dominant, early-onset familial form of AD. [1] [2] [3] Taken together, variation in the three genes only explains approximately 2% of all cases of AD. 4 The fourth gene, apolipoprotein E (APOE), increases the risk for the common late-onset familial and sporadic forms of AD. The disease is associated with the e4 allele, presence of which increases the risk and reduces the average age at onset of AD in a dosedependent manner. [4] [5] [6] [7] [8] Although numerous environmental factors have been linked to AD, the strongest nongenetic risk factor remains old age, with the likelihood of developing AD approximately doubling every 5 years after the age of 65. 9 Segregation analysis of large pedigrees with AD has suggested that, in addition to APOE, many more genetic loci must be associated with AD. 10 This was further supported by various linkage studies, [11] [12] [13] including some that utilised quantitative traits such as age at onset 14 and Ab levels. 15 Although the identification of APP, PS1, PS2 and APOE has significantly advanced the understanding of the aetiology of AD, these loci together explain at most 50% of the genetic component of the disease. 16 Therefore, the search for additional genetic factors that confer a risk for AD is highly warranted, and the advent of genome-wide association studies (GWAS) has greatly facilitated this research. The AlzGene database, 17 which is part of the Alzheimer Research Forum (www.alzforum.org), was established to systematically collate published genetic risk factors for AD and to subject them to constantly updated meta-analyses. With the likely emergence of new targets identified through GWAS, this resource will become increasingly important. In an effort to facilitate the identification of the most promising meta-analysis results available in AlzGene, a continuously updated list of the most strongly associated genes is presented at the Alzforum web site (URL: http://www.alzforum.org/res/com/gen/alzgene/ default.asp). This list of so-called 'Top Results' is ranked by effect size and includes genes that contain at least one variant with a nominally significant summary odds ratio (OR) in the joint analysis of all ethnic groups, or of the samples of Caucasian ancestry. The list excludes genetic variants for which a significant meta-analysis result is likely because of linkage -disequilibrium (LD) with the APOE-e4 allele, as is the case for genes such as TOMM40, APOC1 and APOC2. 18, 19 Furthermore, only genes or genetic variants with a significant OR in each of at least four independent samples of sufficient size are included in the list. Interestingly, at the time of writing this article, four of the top ten genes had first been identified as being associated with AD by GWAS. [20] [21] [22] Although this illustrates the ability of GWAS to unravel previously undetected disease-gene associations, it also highlights the need for follow-up of these results. In the following, we will therefore directly compare the genes listed in the 'Top Results' list of AlzGene with results from a GWAS of a large German cohort, if and where such a comparison is feasible.
Materials and methods

Sample characteristics
This study was approved by the review board of the Munich medical faculty and comprises 491 Caucasian AD patients (278 women and 213 men; mean age: 72.2 years) of German extraction. All patients were recruited by specialists at the outpatient clinic of the Technische Universität Mü nchen. The population-based control group was recruited by the PopGen Biobank, run by the Universitätsklinikum SchleswigHolstein. It comprises 479 Caucasian individuals without AD (222 women and 257 men; mean age: 39.5 years), also of German extraction. No individual included in this cohort has been involved in any previous study, in particular not in one of those published on the AlzGene website. In the cases, the clinical diagnosis of AD was established according to the criteria of the National Institute of Neurological and Communicative Disorders and the StrokeAlzheimer's Disease and Related Disorder Association. 23 After informed consent had been obtained, blood samples were taken by venous puncture. Cognitive performance was assessed using standard neuropsychological tests, such as the Cambridge Cognitive Examination 24 or the test endorsed by the Consortium to Establish a Registry for Alzheimer's Disease, 25 which includes the Mini Mental State Examination. 26 
Genotyping methods
Genotyping was performed by Illumina (San Diego, CA, USA) using their Sentrix HumanHap550 Genotyping BeadChip to interrogate over 555 000 singlenucleotide polymorphism (SNP) loci. The Infinium II assay uses a single tube, whole-genome amplification method that does not require PCR 27, 28 and that enables intelligent SNP selection using tagging SNPs (tagSNPs) from the international HapMap project. 29 The use of tagSNPs improves the efficiency of association studies because a substantial amount of information about a much larger number of SNPs can be obtained by genotyping only this subset of SNPs. In addition to the tagSNPs, HumanHap550 contains approximately 180 mitochondrial SNPs and more than 4300 SNPs from regions recently reported to harbour copy number polymorphism. [30] [31] [32] SNPs were evenly spaced across the genome to ensure most efficient coverage. On average, there is one common SNP (minor allele frequency (MAF) X0.05) located every 5.5, 6.5 and 6.2 kb across the genome in the CEU, CHB þ JPT and YRI populations, respectively. The average 90th percentile of the distance between common SNPs (MAF X0.05) on the HumanHap550 BeadChip is 12, 14 and 14 kb in the CEU, CHB þ JPT and YRI populations, respectively.
Statistics
For each of the SNPs in the GWAS, deviations from Hardy-Weinberg equilibrium were tested for statistical significance using a w 2 -test with 1 degree of freedom. For assessing the possible association of a given SNP with AD, three different genetic models were employed: recessive, dominant or additive. Expected and observed genotype frequencies under the null hypothesis of no disease association were compared by means of a w 2 -test, which yielded an individual P-value for each combination of SNP and genetic model. These P-values were not adjusted for multiple testing because of the explorative nature of the original GWAS. LD was estimated by D 0 and r 2 , haplotype blocks were defined by the confidence interval (CI) approach of Gabriel et al. 33 Allelic and haplotypic associations between SNPs were tested for significance using a w 2 -test as implemented in Haploview v4.1.
34
Figure 1 (a-j) Àlog P-values obtained for single-nucleotide polymorphisms (SNPs) in 10 Alzheimer disease (AD) candidate genes from the AlzGene 'Top Results' list, plus sortilin-related receptor (SORL1; excluding apolipoprotein E (APOE)). Dots represent Àlog P-values for SNPs genotyped within the present genome-wide association study (GWAS) that were not included in the AlzGene database. Triangles mark Àlog P-values for SNPs present in the AlzGene database. Lines between squares represent Àlog P of two-marker haplotypes as calculated with Haploview. The dotted lines at a Àlog P-value of approximately 1.3 demarcate the threshold of nominal significance, that is, P = 0.05.
Comparative SNP analysis SNP selection for a comparison between the GWAS results and the top 10 genes from AlzGene was carried out as follows: All SNPs on the HumanHap550 chip that were located less than 25 kb up-or downstream of the gene in question were identified and included in the analysis. A call rate of more than 99.5% was observed for all SNPs so that no dropouts occurred. When a SNP from the AlzGene meta-analysis was present on the HumanHap550 chip, a direct comparison was made between the respective P-values (that is, AlzGene vs GWAS genotypic and allelic). If such a direct comparison was not possible, the two flanking SNPs of the AlzGene SNP of interest were chosen from the GWAS data. For these two neighbouring SNPs, a two-marker haplotype was created, which allowed (1) estimation of D 0 and r 2 between them and, in the case of high LD, (2) calculation of a haplotypebased statistic to assess the possible disease association of the intermittent AlzGene SNP. P-values were not adjusted for multiple testing because each SNP reported in the 'Top Results' list of AlzGene was deemed an independent hypothesis up for verification.
Results
The 'Top Results' list published online by AlzGene is a summary of meta-analyses results, ranked by effect size. Only genes are included that contain at least one variant with a nominally significant summary OR in the analysis of all ethnic groups combined, or of the samples of Caucasian ancestry. As the most promising meta-analysis results are continuously updated as new data emerge, the list of most strongly ADassociated genes is subject to change, and the following conclusions refer to the version of 7 May 2008. In the following, we will compare in detail the top 10 disease-associated genes from AlzGene, plus the recently interest invoked sortilin-related receptor gene (SORL1; MIM 602005), with the results of our GWAS in the German population. Allele and genotype frequencies for all genotyped SNPs are included in the Supplementary material (Supplementary Table  S1 ) as are most of the local LD structures determined with Haploview ( Supplementary Figures S1-S7 ).
APOE
The strongest GWAS signals were obtained for two intronic SNPs, rs157580 and rs2075650 (both P < 10 À40 ) in the TOMM40 gene (translocase of outer mitochondrial membrane 40 homologue (yeast), MIM 608061), which is in strong LD with the APOE locus, and for two SNPs, rs8106922 and rs405509 (both P < 10 À6 ), located in the APOE promoter. Other strong associations were observed for rs439401, a SNP in the promoter of the apolipoprotein C1 (APOC1) gene (MIM 107710) located downstream of APOE, and for a nonsynonymous promoter SNP, rs5167, in the apolipoprotein C2 (APOC2) gene (MIM 608083).
GAB2
In a previous GWAS, various SNPs across the GRB2-associated binding protein 2 gene (GAB2; MIM 606203) have been reported to modify the AD risk of APOE-e4 carriers. 21 In our study, a total of 27 SNPs in and around GAB2 were analysed (Figure 1a ), 23 of which were located in the immediate GAB2 gene region. A total of 10 SNPs were present in the AlzGene meta-analysis of GAB2, but only one of these, rs4945261, was also genotyped in our study. It was not found to be associated with AD. Similarly, for the nine remaining AlzGene SNPs, analysis of two-marker haplotypes formed by flanking GWAS SNPs yielded no nominally significant disease associations. Likewise, none of the other GAB2 markers gave a significant result. Haplotype analysis revealed two weak association signals (P = 0.037 and P = 0.010) in the single LD block that spanned the entirety of GAB2 (Supplementary Figure S1) . Using a sliding window, this signal could be narrowed down to a two-marker haplotype generated by rs2511175 and rs1981405 (P = 0.033; frequency in AD: 0.147, in controls: 0.110).
CHRNB2
The strongest AD association published for the gene encoding the neuronal nicotinic acetylcholine receptor b2-subunit (CHRNB2; MIM 118507) has been with SNP rs4845378, 35 and this was also the only SNP present in the AlzGene meta-analysis of this gene. Four SNPs from the GWAS were located in CHRNB2, and an additional 12 SNPs were located less than 25 kb up-or downstream of that gene and in neighbouring genes, namely those encoding tudor domain containing 10 (TDR10), ubiquitin-conjugating enzyme E2Q (UBE2Q1) and adenosine deaminase, RNA-specific (ADAR). No direct comparison was possible for rs4845378, and the two-marker haplotype analysis using the flanking SNPs, rs4845652 and rs3811450 did not yield any nominally significant disease association in the GWAS (Figure 1b) . None of the four SNPs located in the CHRNB2 itself showed an association with AD. However, four SNPs within surrounding genes yielded P-values < 0.05, namely an intronic (rs7556449) and a functional SNP (rs3811448) in TDRD10, an intronic SNP (rs7543174) in UBE2Q1 and an intronic SNP (rs9427097) in ADAR. Haplotype analysis of the entire region using Haploview yielded no significant association signals within the two blocks (Supplementary Figure S2) .
CH25H
Two SNPs, rs13500 and rs11594137, 36 were included in the AlzGene meta-analysis of the cholesterol-25-hydroxylase gene (CH25H; MIM 604551), but only the former marker has shown a consistent association with AD before. Five SNPs located within the CH25H gene region and 25 additional SNPs located 25 kb up-and downstream of CH25H were genotyped in our GWAS, including SNPs in the upstream lipase A precursor (LIPA) gene. No direct comparison was possible for rs13500, and none of the two-marker haplotypes generated by flanking SNPs rs4933497 and rs11594137 showed a nominally significant disease association (Figure 1c) . Instead, SNPs rs17117126, located downstream of CH25H, and rs12780342, located within intron 8 of LIPA, appeared to be associated with AD when analysed individually, using a recessive model for the first marker (P = 0.0199, OR = 5.13, 95%CI: 1.12-23.52) and a dominant model for the second marker (P = 0.0377, OR = 1.36, 95%CI: 1.01-1.82). Haplotype analysis yielded a weak association signal only for a twomarker haplotype (rs7922269 and rs6586175) located 11 bp upstream of rs12780342 in intron 8 of the LIPA gene (Supplementary Figure S3) .
PGBD1
In an earlier GWAS of five late-onset AD case-control samples, 22 SNP rs3800324 in exon 5 of the piggyBac transposable element derived 1 (PGBD1) gene( showed evidence for an association with AD. A total of 10 SNPs within the PGBD1 gene region were genotyped in our GWAS, in addition to 19 SNPs 25 kb up-and downstream of the gene. No disease association was observed for rs3800324 (Figure 1d ). However, SNP rs9461448, which is located 960 bp upstream of rs3800324 in intron 4, showed a modest association using a dominant model (P = 0.0193, OR = 1.61, 95%CI: 1.03-2.49). In addition, SNPs rs17312661 and rs7772827 located downstream of PGBD1 in the zinc-finger protein 323 gene (ZNF323) exhibited a comparatively strong association with AD (P = 0.008, OR = 0.71, 95%CI: 0.53-0.94; P = 0.029, OR = 0.76, 95%CI: 0.59-0.98). Two haplotype blocks upstream and downstream of the PGBD1 block were also found to be associated with AD, with the strongest signal observed for the block in ZNF323 (Supplementary Figure S4) .
LMNA
Of the 11 gene regions considered here, the LMNA gene (MIM 150330) encoding the protein lamin A/C yielded the second most significant association with AD in our GWAS (rs9919256, P = 0.00029; Figure 1e ), albeit in an intergenic region 20 kb upstream of the gene. SNPs rs11578696 (upstream), rs915179 (promoter), rs12128066 (downstream) and rs12401573 (downstream) also yielded P-values < 0.05, but only rs915179 was located within the gene itself. A total of 14 SNPs were genotyped in the LMNA gene region in our GWAS, with the five marker mentioned above located in the LMNA gene itself. Of the remaining SNPs, five were located in the SEMA4A gene (MIM 607292). The strongest association published so far for this gene has been with rs505058, 22 but this SNP was not genotyped in our GWAS. Haplotype analysis of the two flanking markers (D 0 = 1) revealed no significant association with AD. However, in the first haplotype block created by Haploview, which includes four SNPs in addition to the significant promoter SNP rs915179, four of the six different haplotypes observed showed a P-value < 0.05. The most significant disease association (P = 0.0006) was observed for haplotype GAAAG (frequency in AD: 0.199, in controls: 0.140; Figure 2 ).
CST3
Numerous studies have investigated the association between AD and variation in the gene encoding cystatin C (CST3; MIM 604312). [37] [38] [39] Three SNPs in this gene were included in the AlzGene list, but only two, rs1064039 and rs5030707, were identified by rs numbers. A total of 16 SNPs from the CST3 region were analysed in our GWAS, four of which were located in the gene itself. Direct comparison of the associated SNPs, rs5030707 and rs1064039, was not possible and none of the flanking two-marker haplotypes (rs2424577 and rs2145231, D 0 = 0.95) revealed a significant association (Figure 1f) . The only nominally significant single marker association was observed for rs16985615, approximately 15 kb upstream of CST3. Haplotype analysis across all 16 SNPs revealed no significant disease associations (Supplementary Figure S5) . 
PCK1
A single SNP, rs8192708, initially identified in another GWAS, 22 was used for the AlzGene metaanalysis of the phosphoenolpyruvate carboxykinase 1 gene (PCK1; MIM 261680). In our GWAS, 34 SNPs in and around PCK1 were analysed, including rs8192708, which is located at the intron 5/exon 6 boundary. Ten of the analysed SNPs were located in the PCK1 gene region. No disease association was observed for marker rs8192708, but a nominally significant association signal could nevertheless be identified in the promoter of PCK1 (rs17411904, P = 0.00331; Figure 1g ). Furthermore, haplotype analysis revealed an associated signal in block 2, including rs17411904, whereas the block including rs8192708 showed no disease association (Figure 3 ). ACE Four SNPs and one insertion/deletion variation were included in the AlzGene meta-analysis of the angiotensin I converting enzyme (ACE) gene (peptidyldipeptidase A1; MIM 106180). In our study, a total of 27 SNPs around this gene were analysed, 14 of which were located within the ACE gene itself. Two AlzGene markers, rs4343 and rs4362, were part of the GWAS but we were not able to replicate their previously reported associations with AD. Indirect analysis of the other two SNPs (rs1800764 and rs4291) through two-marker haplotypes for flanking SNPs rs4459609 and rs4291 (D 0 = 0.97) also revealed no association with AD (Figure 1h ). In fact, none of the GWAS SNPs showed any single marker or haplotype association with AD (Supplementary Figure S6) .
MAPT
The gene encoding microtubule associated protein-t (MAPT; MIM 157140) occurs in two haplotypes H1 (direct orientation) and H2 (inverted orientation). Both haplotypes can be tagged by six markers, [40] [41] [42] but only three of these SNPs, rs1467967, rs242557 and rs3785883, were genotyped in our GWAS. A total of 25 SNPs in the gene region were analysed, 20 of which were located within MAPT itself. Of the three SNPs for which a direct comparison was possible, only rs1467967 in the promoter region yielded a nominally significant single marker association (P = 0.0071; Figure 1i ). None of the flanking two-marker haplotypes for SNPs rs2471738 and rs7521 gave a significant result. However, three additional SNPs analysed in the GWAS were found to be significantly associated with AD (P < 0.05). The most significant signal was obtained for rs3785880 Figure 3 Numerical values are given of D 0 whereas colours were used to encode r 2 . Haplotype blocks and marker combinations with P < 0.05 are highlighted. Blocks followed the haplotype block definition by Gabriel et al., 33 as implemented in Haploview v4.1.
(intron 1, P = 0.00141); the other two signals were observed for an upstream (rs1158660) and a downstream marker (rs6503454, intron 6, hypothetical protein LOC284058), respectively. As we could not determine H1 and H2 haplotypes owing to the lack of genotype information for the six established tagSNPs, we performed a haplotype analysis using Haploview and observed a strong association signal in block 1 (P = 0.0007, frequency in AD: 0.254, in controls: 0.324; Supplementary Figure S7 ).
SORL1
Recently, the SORL1 (MIM 602005) gene has been associated with AD 43, 44 and 29 SNPs within this gene were included in the meta-analysis of AlzGene. We genotyped a total of 50 SNPs in the SORL1 region, 40 of which were located in the gene itself, and 10 were located either up-or downstream within a distance of < 25 kb from the gene. Of the 10 SNPs for which a direct comparison was possible, only minor evidence for a disease association was obtained for two markers in the GWAS, namely rs4935774 (P = 0.045) and rs1614735 (P = 0.033; Figure 1j ). Indirect analysis using flanking marker haplotypes found no association for any of the remaining AlzGene SNPs. However, three additional SNPs were found to yield P-values < 0.05 that have not been reported before: rs12576704 (upstream; P = 0.021), rs10502262 (intron 13; P = 0.031) and rs3781835 (exon 25/intron 25 boundary; P = 0.033). Haplotype analysis revealed only weak association signals (Figure 4) .
Discussion
With the advent of technologies that allow thousands of SNPs across the genome to be genotyped in parallel, genetic research is now equipped for studying the genetic contribution to complex diseases at unprecedented detail. This study is among the first to apply the GWAS approach to AD research. [20] [21] [22] To our knowledge, it represents the first AD GWAS in the German population, the first one using populationbased controls and the first one performed with Illumina technology. Nevertheless, with several GWAS of AD already published, and more being underway, the AlzGene database provides an important tool for ascertaining AD candidate genes that Figure 4 Linkage disequilibrium (LD) structure of the sortilin-related receptor (SORL1) gene, including the haplotype block structure. Numerical values are given of D 0 whereas colours were used to encode r 2 . Haplotype blocks and marker combinations with P < 0.05 are highlighted. Blocks followed the haplotype block definition by Gabriel et al., 33 as implemented in Haploview v4.1.
warrant follow-up with high priority. It is interesting to note that, at the time of writing this article, four of the top ten genes listed by AlzGene were first published as the result of a GWAS. [20] [21] [22] Furthermore, strong associations with genetic variants likely to be in LD with the APOE-e4 allele, such as in the TOMM40, APOC1 and APOC2 genes, have also been identified by our and other GWAS. In this study, the strongest signals were found at the extended APOE locus, in particularly in the TOMM40 gene. Although the respective SNPs, rs157580 and rs2075650, do not coincide exactly with the previously identified signal at rs157581, 22 they nevertheless are located within close proximity (448 bp distance in the case of rs157580).
Whereas the previously observed strong associations between AD and markers at the APOE locus could be consistently replicated in our GWAS, this was not the case for the other 10 genes studied here. Only six of these genes were found to show suggestive associations of nominal significance, most often generated by SNPs other than those reported in AlzGene. The 10 genes studied can be subdivided into two groups: (1) those with associations identified in classical, hypothesis-driven case-control studies and (2) those identified as disease genes through recent GWAS. Six genes investigated in our study fell into the first category and of these, only MAPT and SORL1 showed a nominally significant association in the immediate gene region. Our GWAS did not allow delineation of MAPT H1 and H2 haplotypes, as was the case in previous studies, 42, 45 but the strong disease association of rs1467967 noted here falls into the H1c haplotype that appears to drive the association. Likewise, the strong haplotype-based signal found in the GWAS was localised in the region that delineates H1/H2 MAPT haplotypes.
It has been clear for some time that MAPT is intimately involved in AD pathology because neurofibrillary tangles, together with senile plaques, form the characteristic pathological hallmarks of the disease. Nonetheless, the findings of our GWAS support the hypothesis, coined in previous studies, that MAPT variants are associated with sporadic forms of AD. The SORL1 gene, although not included in the AlzGene 'Top Results' list, has recently attracted great interest, and represents the most thoroughly investigated of all genes studied here. A total of 50 SNPs from the SORL1 region were analysed, 40 of which were located within the immediate gene region. SORL1 is also one of the genes with the largest number of SNPs included in the AlzGene meta-analyses. Only two of the ten SNPs that allowed a direct comparison yielded a weak association signal in our GWAS. Indirect analysis of the remaining SNPs gave no nominally significant result at all although a marginal association was found for three SNPs not reported in AlzGene. Although these results still require validation, taken together with previous reports 43, [46] [47] [48] our data appear to support at least a modest disease association of SORL1, a gene that encodes a product implicated in the regulation of processing and trafficking of the APP.
The CHRNB2 ranks number three on the AlzGene 'Top Results' list. This gene, which encodes the b2-subunit of the neuronal nicotinic acetylcholine receptor, was reported to be associated with AD in a single study before 35 but the result could not be replicated in other cohorts. In this study, indirect analysis of the associated SNP also failed to unravel any significant disease association. However, the comparison may not have been very efficient because of the LD structure of the respective gene region. Although no signal was observed within CHRNB2 itself, an association became evident with variants in three genes from the surrounding 25 kb region, including a functional SNP within exon 9 of TDRD10, which results in a valine to isoleucine substitution at position 101 of the encoded amino-acid chain. This result requires replication to confirm its validity and, likewise, its functional relevance would need to be investigated as well.
A similar scenario emerged for the fourth gene on the list, CH25H, encoding cholesterol-25-hydroxylase. The single SNP with a significant association in AlzGen, rs13500, could only be analysed indirectly in our GWAS and revealed no association. Nonetheless, weak association signals were observed downstream and within the LIPA gene. Significant association signals have not been reported before for this gene. Accordingly, the AlzGene meta-analysis of LIPA was negative but only a single SNP 49 25 kb distal to the association signal observed in our study was included in that analysis. Additional SNPs within LIPA that were presented on the AlzGene site but had not undergone meta-analysis also failed to show any association with AD in our GWAS. The seventh and ninth genes on the 'Top Results' list, CST3 and ACE, respectively, yielded no association signals in either the direct or indirect assessment of our GWAS results. With only one exception, none of the single markers or haplotypes within these genes or in regions 25 kb up-and downstream yielded a significant association. The only exception was rs16985615, located in the intergenic region 15 kb upstream of CST3.
Four of the genes investigated in our study fell into the second category, that is, were first reported as a result of a GWAS. Of all the 13 SNPs in these genes that underwent AlzGene meta-analysis, only three were present on the Sentrix HumanHap550 Genotyping BeadChip. However, their previously published associations with AD could not be replicated in our GWAS. Nevertheless, all four genes showed some association with AD, but not with previously reported markers and in most cases with smaller effect sizes. In the case of GAB2, only one of the ten SNPs originally reported to be associated with AD by Reiman et al. 21 could be compared directly, but to no effect, and indirect comparisons also revealed no nominally significant association signals. However, haplotype analysis highlighted a single block that covers the entire gene and that showed a weak association with AD. This signal was narrowed down to a two-marker haplotype, comprising rs2511175 and rs1981405, which is located 14 kb downstream and 9 kb upstream of two previously reported signals by SNPs rs4945261 and rs2510038, respectively. Owing to the nature of the LD structure and the number of SNPs investigated, it appears unlikely that any additional signals have been missed. Therefore, the data suggests that GAB2 contributes only little to the risk for AD in the German population.
The remaining three genes, PGBD1, PCK1 and LMNA were initially reported as involving in AD by Grupe et al. 22 In all three instances, a single SNP was reported to be disease associated, but only two of the three SNPs were analysed in our GWAS. The association signals for these two SNPs, one each in PGBD1 and PCK1, were not replicated here. In the case of PGBD1, similar genotype frequencies were observed as reported previously. However, although the AD-associated SNP in PGBD1 had been found to be significant in an earlier meta-analysis of five studies, 22 it was only significant in one study on its own. Although the PGBD1 signal could not be replicated directly in our GWAS, other signals were identified in that gene, including one SNP located less than 1 kb upstream of the previously reported SNP. These findings indicate that PGBD1 needs to be examined further to determine the precise nature of its function in AD, especially in view of its specific expression in brain. For PCK1, previous disease association also could not be replicated directly in our GWAS, but new signals at other SNPs in the gene were observed. Here, the associated individual SNP, rs17411904, was located in the promoter region. Furthermore, a haplotype block spanning the promoter region and including the associated SNP was also found to be associated with AD. PCK1, in particularly the promoter region of the gene, has also been implicated as a risk factor for type 2 diabetes mellitus 50 and is thus a promising candidate for further investigation, bearing in mind previous epidemiological links between diabetes and AD. 51 The results for LMNA follow the same trend as the other genes, where the original association signal could not be replicated but where new signals were identified, although a direct comparison of the results was not possible for LMNA. Like with PCK1, the association with LMNA was localised to the promoter region of the gene. Furthermore, the strongest signal of all SNPs investigated in this study was located within a haplotype spanning the promoter region of the LMNA gene, although the SNP itself, rs9919256, was located in an intergenic region approximately 20 kb upstream. Variation LMNA has been linked to numerous disorders (http://www.ncbi.nlm.nih.gov/ entrez/dispomim.cgi?id = 150330) although its function in AD has not been investigated so far. As the only studies linking LMNA to AD have been GWAS, where the associated signals were approximately 28 kb apart, the respective associations require replication through fine mapping to determine their validity.
In addition to the APOE locus, our GWAS of AD in the German population can be seen to have identified nominally significant disease association for six of ten candidate genes investigated, albeit predominantly in SNPs other than those published before. The major reason for this is that a GWAS cannot include all existing SNPs but must be confined to SNPs that provide the best coverage of the genome. In the case of the Illumina platform, utilised in our study, a recent report suggested that, of the two commercial platforms currently used for AD GWAS, it has a slightly better coverage. 52 Regardless of this, GWAS-derived SNPs in the AlzGene 'Top Results' yielded more suggestive association signals in our studies than markers identified in gene-based case-control studies. In conclusion, our comparison of the 'Top Results' genes with association signals from a GWAS in the German population supported a disease association of over 50% of previously reported disease genes, but at the same time reinforces the necessity that these associations need replication and validation in multiple populations. This view is supported by the fact that the causal variant, if any, has not yet been identified in any of the genes involved, and that most association signals therefore may have arisen from (population-dependent) LD. In addition, cross-platform comparison may also lead to the identification of new association signals. Finally, our study confirms that GWAS, regardless of the platform used, are valuable tools for the identification of genetic variants associated with complex human diseases like AD.
